Shares in US mRNA specialist Moderna (Nasdaq: MRNA) were 7% higher during Thursday morning’s trading.
The Boston-based company earlier announced its financial results for the first quarter of 2024 and its latest estimates for the year ahead.
"This is the start of a banner year for our vaccine platform"Total revenue for the quarter was $167 million, compared to $1.9 billion in the same period in 2023. The decline was primarily due to reduced sales of the company's Spikevax COVID-19 vaccine. Indeed, revenue from the shot dropped roughly 90% from the same period a year ago. Of the $167 million in Spikevax sales, $100 million came in the USA and $67 million were elsewhere.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze